Table 3.
GluCEST contrast ratios in peritumoural region according to clinical variables.
| Clinical variable (n = subjects with variable present/absent) | Peritumoural GluCEST contrast intensity ratio in patients with clinical variablea | Peritumoural GluCEST contrast intensity ratio in patients without clinical variablea | P value |
|---|---|---|---|
| TAE (n = 7/2) | 1.02 +/− 0.09 | 0.90 +/− 0.00 | 0.115 |
| Seizure in month prior to 7 T acquisition (n = 5/4) | 1.04 +/− 0.75 | 0.93 +/− 0.06 | 0.038 |
| DRE (n = 2/7) | 1.07 +/− 0.00 | 0.97 +/− 0.09 | 0.029 |
| Radiological Progression since Dx (n = 6/3) | 0.98 +/− 0.08 | 1.02 +/− 0.11 | >0.99⁎ |
| Any adjuvant therapy (n = 4/5) | 1.01 +/− 0.09 | 0.98 +/− 0.10 | >0.99⁎ |
TAE = tumour associated epilepsy; Sz = seizure. Dx = diagnosis; DRE = drug resistant epilepsy.
a
Ratio of GluCEST contrast intensity in peritumoural region to ‘contralateral unaffected ROI-P'.
⁎
Bonferroni corrected p value.